In their in vitro model, they demonstrated that the P2X7R antagonist AZ10606120 significantly reduced GM-CSF levels and GBM cell proliferation, exhibiting a superior tumor-killing effect compared to TMZ, the current first-line treatment for GBM. This evidence concerns the gene CSF2 and neoplasm.